SEP 20, 2020 5:08 AM PDT

Revealing the Structure of Hallucinogens Bound to Their Receptor

WRITTEN BY: Carmen Leitch

Recent studies have demonstrated that hallucinogenic drugs like LSD, psilocybin, and mescaline have therapeutic potential. Studies have shown that they can improve the symptoms of depression and anxiety, for example. But patients with those problems would obviously have to tolerate the significant effects of the drugs if they were to become an option for treatment. Their potential for abuse has also made them difficult to study. Researchers are working towards understanding how these drugs work on a molecule level. It may be possible to create beneficial drugs that can work therapeutically without hallucinations, or alter them so new medications can be created.

This illustration shows the chemical architecture of amino acids that make up the 5-HT2A serotonin receptor complex bound to a psychedelic compound (pink, top) Credit: Roth Lab (UNC School of Medicine)

Reporting in Cell, scientists have revealed the structure of the 5-HT2A serotonin receptor (HTR2A), a cell-surface receptor known to bind hallucinogens, while it's bound to LSD, psilocybin, and mescaline.

"Millions of people have taken these drugs recreationally, and now they are emerging as therapeutic agents," said co-senior study author Bryan L. Roth, M.D., Ph.D., the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina School of Medicine. "Gaining this first glimpse of how they act at the molecular level is really important, a key to understanding how they work. Given the remarkable efficacy of psilocybin for depression (in Phase II trials), we are confident our findings will accelerate the discovery of fast-acting antidepressants and potentially new drugs to treat other conditions, such as severe anxiety and substance use disorder."

There are high levels of HTR2A in the cerebral cortex, and researchers have suggested that it's crucial to the effects of hallucinogens.

"When activated, the receptors cause neurons to fire in an asynchronous and disorganized fashion, putting noise into the brain's system," said Roth. "We think this is the reason these drugs cause a psychedelic experience. But it isn't at all clear how these drugs exert their therapeutic actions."

Roth's lab worked with the lab of Stanford University School of Medicine structural biologist Georgios Skiniotis, Ph.D. "A combination of several different advances allowed us to do this research," Skiniotis said. "One of these is better, more homogeneous preparations of the receptor proteins. Another is the evolution of cryo-electron microscopy technology, which allows us to view very large complexes without having to crystalize them."

Study co-first author and Skiniotis lab postdoctoral researcher Kuglae Kim, Ph.D., played an integral part in the work.

"Kuglae was amazing," Roth said. "I'm not exaggerating when I say what he accomplished is among the most difficult things to do. Over three years in a deliberate, iterative, creative process, he was able to modify the serotonin protein slightly so that we could get sufficient quantities of a stable protein to study."

This enabled the team to generate the X-ray crystallography structure of LSD bound to HTR2A for the first time. The researchers used cryo-EM to create images of a candidate hallucinogen called 25-CN-NBOH, bound to the receptor and a complex including the effector protein Gαq. This complex is involved in neurotransmitter release.

Image credit: Pixabay

"The more we understand about how these drugs bind to the receptors, the better we'll understand their signaling properties," Skiniotis said. "This work doesn't give us the whole picture yet, but it's a fairly large piece of the puzzle."

Sources: AAAS/Eurekalert! via University of North Carolina Health Care, Cell

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
FEB 10, 2021
Drug Discovery & Development
Black Men Respond Best to Immunotherapy for Prostate Cancer
FEB 10, 2021
Black Men Respond Best to Immunotherapy for Prostate Cancer
Researchers from Northwestern University have found that Black men and men of African ancestry respond better than men f ...
FEB 15, 2021
Microbiology
How Good Bacteria Go Bad
FEB 15, 2021
How Good Bacteria Go Bad
Bacteria have colonized nearly every environment on Earth, including the human body. While most of the microbes we encou ...
FEB 18, 2021
Cell & Molecular Biology
Inhibition of a Specific Enzyme Could be a Way to Treat Glioblastoma
FEB 18, 2021
Inhibition of a Specific Enzyme Could be a Way to Treat Glioblastoma
Researchers may have identified a new treatment target for a deadly form of brain cancer. Inhibiting an enzyme called PR ...
FEB 25, 2021
Immunology
Two Immune Guardians of the Brain Discovered
FEB 25, 2021
Two Immune Guardians of the Brain Discovered
Most organ systems are protected by a cavalry of immune cells present in the circulation—but not the brain. Consid ...
MAR 11, 2021
Cell & Molecular Biology
Deadly Cancer Cells Can Move in the Wrong Direction
MAR 11, 2021
Deadly Cancer Cells Can Move in the Wrong Direction
Cancer is most deadly when it metastasizes; when cells break away from a primary site of cancer and move through the bod ...
MAR 17, 2021
Cell & Molecular Biology
A Critical Step in the Development of Brain Disease is ID'ed
MAR 17, 2021
A Critical Step in the Development of Brain Disease is ID'ed
Some brain diseases including mad cow disease and the human version Creutzfeldt-Jakob disease (CJD), Kuru, and fatal fam ...
Loading Comments...